Deferred Federal Income Tax Expense (Benefit) in USD of INTEGRATED BIOPHARMA INC from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
INTEGRATED BIOPHARMA INC quarterly/annual Deferred Federal Income Tax Expense (Benefit) history and change rate from Q3 2020 to Q3 2025.
  • INTEGRATED BIOPHARMA INC Deferred Federal Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $51K, a 73.2% decline year-over-year.
  • INTEGRATED BIOPHARMA INC Deferred Federal Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was $1.25M, a 305% increase year-over-year.
  • INTEGRATED BIOPHARMA INC annual Deferred Federal Income Tax Expense (Benefit) for 2025 was $1.39M, a 1018% increase from 2024.
  • INTEGRATED BIOPHARMA INC annual Deferred Federal Income Tax Expense (Benefit) for 2024 was $124K, a 125% increase from 2023.
Deferred Federal Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Quarterly Change (%)
Deferred Federal Income Tax Expense (Benefit), Annual (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Annual Change (%)

INTEGRATED BIOPHARMA INC Quarterly Deferred Federal Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.25M $51K -$139K -73.2% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025
Q2 2025 $1.39M $735K +$622K +550% 01 Apr 2025 30 Jun 2025 10-K 23 Sep 2025
Q1 2025 $764K $415K +$334K +412% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025
Q4 2024 $430K $46K +$122K 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $308K $190K +$184K +3067% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025
Q2 2024 $124K $113K +$25K +28.4% 01 Apr 2024 30 Jun 2024 10-K 23 Sep 2025
Q1 2024 $99K $81K +$72K +800% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025
Q4 2023 $27K -$76K -$72K -1800% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 $99K $6K +$44K 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 $55K $88K 01 Apr 2023 30 Jun 2023 10-K 20 Sep 2024
Q1 2023 $9K +$115K 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024
Q4 2022 -$4K +$440K +99.1% 01 Oct 2022 31 Dec 2022 10-Q 12 Feb 2024
Q3 2022 -$38K $0 0% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q1 2022 -$106K +$295K +73.6% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$444K -$696K -276% 01 Oct 2021 31 Dec 2021 10-Q 10 Feb 2023
Q3 2021 -$38K -$311K -114% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q1 2021 -$401K 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022
Q4 2020 $252K 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022
Q3 2020 $273K 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021

INTEGRATED BIOPHARMA INC Annual Deferred Federal Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2025 $1.39M +$1.26M +1018% 01 Jul 2024 30 Jun 2025 10-K 23 Sep 2025
2024 $124K +$69K +125% 01 Jul 2023 30 Jun 2024 10-K 23 Sep 2025
2023 $55K 01 Jul 2022 30 Jun 2023 10-K 20 Sep 2024
* An asterisk sign (*) next to the value indicates that the value is likely invalid.